Accessibility Menu
Decision Diagnostics logo

Decision Diagnostics(OTC) DECN

Market Cap$400.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Decision Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-24
Decision Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-13
1 month+0%USD 0.002026-07-20
3 month+0%USD 0.002026-05-21
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-08-18
3 year-99%USD 0.002023-08-24
5 year-99.99%USD 0.012021-08-25
Since inception-100%USD 56.572002-02-07

Decision Diagnostics Financials at a Glance

Market Cap

$400.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.13M

Net Income (TTM)

-$8.78M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-6.70 (Low)

Price

$0.00

Volume

1,200

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Nov 27, 2024

DECN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Decision Diagnostics

Decision Diagnostics Corp. specializes in developing electronic medical record technologies optimized for smartphones. The company offers a range of diagnostic solutions and home-use testing products, primarily focusing on chronic illness management.

Products and Services
  • GenUltimate! glucose test strips for personal use
  • PetSure! glucose test strips for pets
  • MD@Hand, a comprehensive management system for healthcare
Growth Outlook
  • Recent quarterly revenue of $518,511 shows potential for growth
  • Gross profit margin improved to 22.23% in Q3 2021
  • Focus on mobile-centric e-health products aligns with market trends
Financial Highlights
  • Trailing twelve months revenue of $2.2 million indicates steady performance
  • Operating expenses totaled $1.1 million in Q3 2021
  • Cash and cash equivalents at $210,851 as of September 30, 2021
Decision Diagnostics Corp. has positioned itself within the healthcare sector, focusing on innovative solutions for both human and animal health. The company's product offerings, particularly in glucose monitoring, cater to a growing market of individuals managing diabetes and other chronic conditions. With a commitment to developing mobile-centric technologies, Decision Diagnostics aims to enhance patient care through accessible and efficient solutions. Recent financial data suggests a steady revenue stream, with improvements in gross profit margins, indicating potential for future growth. The company's focus on intellectual property and technological innovation further strengthens its market position, making it an intriguing option for investors interested in the healthcare technology space.
AI Generated • Aug 21, 2026

Industry

Health Care Technology

Headquarters

Westlake Village, CA 91361, US

DECN Financials

Key Financial Metrics (TTM)

Gross Margin

25.18%

Operating Margin

-106.68%

Net Income Margin

-1499.05%

Return on Equity

-10388.57%

Return on Capital

-61.94%

Return on Assets

-524.76%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$400.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

380.49M

Volume

1.20K

Avg. Volume

15.79K

Financials (TTM)

Gross Profit

$462.23K

Operating Income

-$1.93M

EBITDA

-$2.10M

Operating Cash Flow

-$1.07M

Capital Expenditure

-$36.88K

Free Cash Flow

-$1.11M

Cash & ST Invst.

$210.85K

Total Debt

$3.24M

Decision Diagnostics Performance Analysis

Decision Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42020-12-310.2%
Q12021-03-313.1%
Q22021-06-302.7%
Q32021-09-30-6.1%
Decision Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42020-12-31-41.3%
Q12021-03-3187.7%
Q22021-06-3070.4%
Q32021-09-30-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2021YOY CHG

Revenue

$518.51K

-0.4%

Gross Profit

$115.28K

+20.1%

Gross Margin

22.23%

N/A

Market Cap

$400.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$66.67

N/A

Employees

6

N/A

Net Income

-$554.92K

+88.3%

EBITDA

-$490.72K

-74.4%

Quarterly Fundamentals

Name
Q3 2021YOY CHG

Total Cash

$210.85K

-65.7%

Total Debt

$3.24M

-3.9%

Accounts Receivable

$897.67K

-24.8%

Inventory

$165.61K

-12.1%

Long Term Debt

$0.00

N/A

Short Term Debt

$3.35M

-7.0%

Return on Assets

-5.25%

N/A

Return on Invested Capital

-2.90%

N/A

Free Cash Flow

-$62.09K

+89.5%

Operating Cash Flow

-$60.47K

+89.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AXMPAXM Pharma, Inc.
$0.00+0.00%
IBXGiBX Group, Inc.
$0.00+0.00%
ROTHPharmaRoth Labs, Inc.
$0.00+0.00%
PRMDPrimeMD Inc
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CRECre8 Enterprise
$6.60+1.57%
BITOProShares Trust - ProShares Bitcoin ETF
$10.50-0.01%
NVDANvidia
$210.97-0.01%
DAICCid HoldCo
$5.15+0.33%

Questions About DECN

What is the current price of Decision Diagnostics?

Decision Diagnostics is trading at $0.00 per share.

What is the 52-week range for Decision Diagnostics?

Over the past 52 weeks, Decision Diagnostics has traded between $0.00 and $0.00.

How much debt does Decision Diagnostics have?

Decision Diagnostics total debt is unavailable.

How much cash does Decision Diagnostics have on hand?

Decision Diagnostics does not have cash on hand data available.

What is Decision Diagnostics’s dividend yield?

Decision Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.